{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:23:53Z","timestamp":1791563033476,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.transci.2020.102819","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T20:51:26Z","timestamp":1590439886000},"page":"102819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"D.","family":"Laszlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GP.","family":"Marcacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rabascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Magar\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Caime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MT.","family":"Lionetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11 November","key":"10.1016\/j.transci.2020.102819_bib0005","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.3324\/haematol.2019.228684","article-title":"Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?","volume":"104","author":"Engelhardt","year":"2019","journal-title":"Haematologica"},{"issue":"October","key":"10.1016\/j.transci.2020.102819_bib0010","article-title":"Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial","volume":"3","author":"Bringhen","year":"2019","journal-title":"Haematologica"},{"issue":"11 November","key":"10.1016\/j.transci.2020.102819_bib0015","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3324\/haematol.2018.205476","article-title":"Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial","volume":"104","author":"Wester","year":"2019","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"10.1016\/j.transci.2020.102819_bib0020","article-title":"Autologous stem cell transplantation versus Bortezomib-Melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102819_bib0025","first-page":"1904","volume":"23","author":"Giralt","year":"2009"},{"issue":"5 May","key":"10.1016\/j.transci.2020.102819_bib0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2010.08.018","article-title":"Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide","volume":"17","author":"Shaughnessy","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5 October","key":"10.1016\/j.transci.2020.102819_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21280","article-title":"Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF","volume":"28","author":"Chaudhary","year":"2013","journal-title":"J Clin Apher"},{"issue":"10 October","key":"10.1016\/j.transci.2020.102819_bib0040","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/bmt.2013.52","article-title":"Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies","volume":"48","author":"Awan","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7 July","key":"10.1016\/j.transci.2020.102819_bib0045","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.transci.2020.102819_bib0050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"8 August","key":"10.1016\/j.transci.2020.102819_bib0055","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/bmt.2011.216","article-title":"European data on stem cell mobilization with plerixafor in non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization","volume":"47","author":"H\u00fcbel","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.transci.2020.102819_bib0060","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102819_bib0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/bmt.2010.54","article-title":"Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data","volume":"46","author":"Duarte","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"2 Febuary","key":"10.1016\/j.transci.2020.102819_bib0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12 December","key":"10.1016\/j.transci.2020.102819_bib0075","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2015.190","article-title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","volume":"50","author":"Uy","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"2 Febuary","key":"10.1016\/j.transci.2020.102819_bib0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1537-2995.2004.04210.x","article-title":"Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells","volume":"45","author":"Abrahamsen","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2020.102819_bib0085","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/cncr.31175","article-title":"Telomerase reverse transcriptase promoter alterations across cancer types as detected by next\u2010generation sequencing: a clinical and molecular analysis of 423 patients","volume":"124","author":"Schwaederle","year":"2017","journal-title":"Cancer"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220301142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220301142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:51:40Z","timestamp":1761468700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220301142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1473050220301142"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.102819","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.102819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102819"}}